Molecules involved in these pathways have been shown to activate the PI3K-AKT axis and NFκB, as demonstrated by the use of a γ-secretase (GSI), and Notch-1 inhibitors in pancreatic, colorectal and breast cancers [26–28]. This evidence concerns the gene AKT1 and breast carcinoma.